title: [Nasopharyngeal cancers, an overview].
abstract: Cancer of the nasopharynx is an uncommon malignancy in France (incidence  =  0.5/year/100,000 men) but is endemic in areas like in South-East Asia. Exclusive radiation therapy used to be the standard and results in local control rates for T3-T4 tumors around 50-75 %. Intensity-modulated radiotherapy (IMRT) improves tumor coverage with a sparing of organs at risk and has to be privileged. Concurrent chemotherapy with IMRT achieved significant survival benefice with 5-year overall survival above 75 %. Concurrent radiochemotherapy with platinum is the most frequent scheme but induction and adjuvant chemotherapies are discussed to reduce distant failure: studies are currently ongoing. Follow-up aims to detect early local failures with a chance of cure and to manage long-term toxicities.
authors.affiliation: CHU de la Milétrie, Service d'oncologie radiothérapique, 2, rue de la Milétrie, 86000 Poitiers, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Jardel
authors.affiliation: Centre Antoine-Lacassagne, Service d'oncologie radiothérapie, 33, avenue Valombrose, 06189 Nice, France, Institut universitaire de la face et du cou, 33, avenue Valombrose, 06189 Nice, France, Université Nice-Sophia Antipolis, 33, avenue Valombrose, 06189 Nice, France.
authors.forename: Juliette
authors.initials: J
authors.lastname: Thariat
authors.affiliation: Institut Gustave-Roussy, Service d'oncologie radiothérapie, 94000 Villejuif, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Blanchard
authors.affiliation: CHU Habib Bourguiba, Service de cancérologie médicale, 3029 Sfax, Tunisie.
authors.forename: Fatma
authors.initials: F
authors.lastname: Elloumi
authors.affiliation: CHU Habib Bourguiba, Service de cancérologie médicale, 3029 Sfax, Tunisie.
authors.forename: Nabil
authors.initials: N
authors.lastname: Toumi
authors.affiliation: CHU de la Milétrie, Service d'oncologie radiothérapique, 2, rue de la Milétrie, 86000 Poitiers, France.
authors.forename: René-Jean
authors.initials: RJ
authors.lastname: Bensadoun
authors.affiliation: CHU Habib Bourguiba, Service de cancérologie médicale, 3029 Sfax, Tunisie.
authors.forename: Mounir
authors.initials: M
authors.lastname: Frikha
authors.affiliation: CHU Habib Bourguiba, Service de cancérologie médicale, 3029 Sfax, Tunisie.
authors.forename: Jamel
authors.initials: J
authors.lastname: Daoud
authors.affiliation: CHUV Centre hospitalier universitaire vaudois, Service de radio-oncologie, rue du Bugnon 21, 1011 Lausanne, Vaud, Suisse.
authors.forename: Jean
authors.initials: J
authors.lastname: Bourhis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000473:pathology* / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D011878:Radiotherapy; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents
keywords: IMRT; chemotherapy; nasopharyngeal cancer; radiation therapy